IMMUNIC, INC. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Daniel Vitt's employment terminated August 7, 2026, with severance of ~$946k (base salary for 16.5 months plus 75% of 2026 bonus = $670k lump sum + $276.4k bonus + €18k/month healthcare for 18 months). He transitions to unpaid Founder/Chair of Scientific Advisory Board role with €15k/month consulting agreement (12 months, ≤15 hrs/month). Non-compete and IP restrictions imposed. Simultaneously, Immunic appointed Erik Lundgren as CEO (May 22, 2026), Michael Panzara as Chief Medical Officer (April 24, 2026), Michael Bonney as Board Chair (May 16, 2026), and Elena Ridloff to Board (August 6, 2026). Company has €155.1M cash; Q2 2026 net loss was $34.1M.
Why this rating
Founder departure is material leadership change (60–84 range). Severance (~$1.1M total) is ~1.3% of market cap but manageable given €155.1M cash runway into late 2027. Simultaneous replacement of top team with experienced MS executives (Lundgren from Roche/Genentech, Panzara from Biogen/Sanofi) offsets disruption risk. Phase 3 readout pending end-2026 dominates outlook.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.